Clinical Report: Utilizing Long-Read Sequencing in Liquid Biopsy for Enhanced Precision in Oncology

Overview

Long-read sequencing (LRS) technologies are emerging as a promising approach in liquid biopsy for cancer diagnosis and monitoring. LRS offers advantages over short-read sequencing by enabling the detection of structural variants and epigenetic modifications, which are critical for understanding tumor heterogeneity.

Background

Liquid biopsy represents a minimally invasive method for analyzing tumor-derived genetic material from bodily fluids, facilitating real-time insights into cancer evolution. While short-read sequencing has been widely adopted, it has limitations in detecting complex genomic rearrangements and epigenetic changes. The advancement of LRS technologies could enhance the precision of liquid biopsy, particularly in characterizing cancer genomes and epigenomes.

Data Highlights

No numerical data provided in the source material.

Key Findings

• Long-read sequencing (LRS) can detect structural variants, haplotype phasing, and fusion transcripts that short-read sequencing cannot.
• LRS technologies include single-molecule real-time (SMRT) and nanopore sequencing, both of which produce longer reads than short-read NGS.
• LRS allows for direct methylation profiling without bisulfite conversion, preserving important genomic features.
• Emerging studies indicate LRS's feasibility for analyzing cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) across various cancer types.
• Current barriers to LRS implementation include pre-analytical variability, cost, and high computational demands.

Clinical Implications

The integration of LRS into liquid biopsy workflows may enhance the detection of complex genomic alterations and improve patient monitoring. As sequencing technologies evolve, LRS could play a vital role in precision oncology by providing comprehensive tumor profiling.

Conclusion

Long-read sequencing represents a significant advancement in liquid biopsy technology, with the potential to improve cancer diagnosis and monitoring through enhanced genomic characterization.

Related Resources & Content

1. the pathologist, Decentralized Liquid Biopsy Testing for Comprehensive Genomic Profiling, 2026 -- Decentralized Liquid Biopsy Testing for Comprehensive Genomic Profiling
2. the pathologist, Liquid Biopsy Supports Precision Oncology, 2026 -- Liquid Biopsy Supports Precision Oncology
3. the pathologist, Implementation of a large liquid biopsy genomic profiling assay in a decentralized setting, 2026 -- Implementation of a large liquid biopsy genomic profiling assay in a decentralized setting
4. Franklin / MDSpire, Liquid Biopsy Demonstrates Clinical Utility Across GI Cancers, NSCLC, and Colorectal Cancer Treatment Guidance, 2025 -- Liquid Biopsy Approaches for Cancer Characterization, Residual Disease Detection, and Therapy Monitoring | American Society of Clinical Oncology Educational Book
5. Liquid Biopsy Testing – Solid Tumors, 2025 -- Liquid Biopsy Testing – Solid Tumors
6. ASCO's Draft Guidelines for ctDNA Testing in Solid Tumors/Lymphoma Public Comment Period Open, 2025 -- ASCO's Draft Guidelines for ctDNA Testing in Solid Tumors/Lymphoma Public Comment Period Open
7. Colon cancer: ctDNA-guided adj chemo not ready for prime time?, 2025 -- Colon cancer: ctDNA-guided adj chemo not ready for prime time?
8. The prognostic and clinical utility of circulating tumor DNA in diffuse large B-cell lymphoma: a systematic review and meta-analysis, 2025 -- The prognostic and clinical utility of circulating tumor DNA in diffuse large B-cell lymphoma: a systematic review and meta-analysis
9. Predictive role of circulating tumor DNA based molecular residual disease for long-term outcomes in non-small cell lung cancer patients: a meta-analysis, 2025 -- Predictive role of circulating tumor DNA based molecular residual disease for long-term outcomes in non-small cell lung cancer patients: a meta-analysis
10. Circulating tumour DNA assays in focus: highlights from ASCO 2025 for clinicians, 2025 -- Circulating tumour DNA assays in focus: highlights from ASCO 2025 for clinicians
11. Nanopore-based consensus sequencing enables accurate multimodal tumor cell-free DNA profiling, 2025 -- Nanopore-based consensus sequencing enables accurate multimodal tumor cell-free DNA profiling
12. Nanopore-based cell-free DNA fragmentation and methylation profiles from the cerebral spinal fluid of patients with lung cancer brain metastases, 2025 -- Nanopore-based cell-free DNA fragmentation and methylation profiles from the cerebral spinal fluid of patients with lung cancer brain metastases
13. SAVANA: reliable analysis of somatic structural variants and copy number aberrations using long-read sequencing, 2025 -- SAVANA: reliable analysis of somatic structural variants and copy number aberrations using long-read sequencing
14. Franklin / MDSpire — Liquid Biopsy Demonstrates Clinical Utility Across GI Cancers, NSCLC, and Colorectal Cancer Treatment Guidance
15. Liquid Biopsy Approaches for Cancer Characterization, Residual Disease Detection, and Therapy Monitoring | American Society of Clinical Oncology Educational Book
16. Liquid Biopsy Testing – Solid Tumors
17. ASCO's Draft Guidelines for ctDNA Testing in Solid Tumors/Lymphoma Public Comment Period Open - Guideline Central
18. Colon cancer: ctDNA-guided adj chemo not ready for prime time?
19. The prognostic and clinical utility of circulating tumor DNA in diffuse large B-cell lymphoma: a systematic review and meta-analysis | npj Precision Oncology
20. Predictive role of circulating tumor DNA based molecular residual disease for long-term outcomes in non-small cell lung cancer patients: a meta-analysis | World Journal of Surgical Oncology | Springer Nature Link
21. Circulating tumour DNA assays in focus: highlights from ASCO 2025 for clinicians | BJC Reports
22. Nanopore-based consensus sequencing enables accurate multimodal tumor cell-free DNA profiling - PMC
23. Nanopore-based cell-free DNA fragmentation and methylation profiles from the cerebral spinal fluid of patients with lung cancer brain metastases - PubMed
24. SAVANA: reliable analysis of somatic structural variants and copy number aberrations using long-read sequencing | Nature Methods